VENUS MEDTECH-B (02500) has met all resumption guidelines and will resume trading on March 13th.

12/03/2025

GMT Eight

Venus Medtech-B (02500) announced that the company has met all the conditions for resumption of trading. The company has applied to resume trading of its shares on the Stock Exchange at 9:00 am on March 13, 2025.

MILLION CITIES (02892) issued a profit warning, expecting the annual net loss after tax to narrow to 1.43 billion to 2.43 billion, compared to the same period last year.

Situwei (688213.SH) shareholders and directors plan to reduce their shareholding by up to 2.99%.

Contact: contact@gmteight.com

VENUS MEDTECH-B (02500) has met all resumption guidelines and will resume trading on March 13th.

RECOMMEND

US Stock Market Move | The weight loss drug Cagrisema's clinical trial results did not meet expectations. Novo Nordisk A/S Sponsored ADR Class B (NVO.US) dropped more than 5%.

Asiayang Group (01907) is planning an asset + cash transaction, and may take control of SINOHYTEC (688339.SH,02402) to expand its hydrogen industry chain layout.

Former US Treasury Secretary Mnuchin: Market reaction to Trump administration policies is excessive and unlikely to lead to economic recession.